2015 AAHA/AAFP Pain Management Guidelines for Dogs and Cats

**Rationale:** The robust advances in pain management for companion animals underlie the decision of the American Animal Hospital Association (AAHA) and American Association of Feline Practitioners (AAFP) to expand on the information provided in the 2007 AAHA/AAFP Pain Management Guidelines. The 2015 Guidelines summarize and offer a discriminating review of much of this new knowledge.

**Relevance:** Pain management is central to veterinary practice, alleviating pain, improving patient outcomes, and enhancing both quality of life and the veterinarian–client–patient relationship. These Guidelines support veterinarians in incorporating pain management into practice, improving patient care.

**Approaches:** The management of pain requires a continuum of care that includes anticipation, early intervention, and evaluation of response on an individual patient basis. A team-oriented approach, including the owner, is essential for maximizing the recognition, prevention and treatment of pain in animals.

**Evidence base:** The Guidelines include both pharmacologic and non-pharmacologic modalities to manage pain; they are evidence-based insofar as possible and otherwise represent a consensus of expert opinion. Behavioral changes are currently the principal indicator of pain and its course of improvement or progression, and the basis for recently validated pain scores. Post-surgical pain is eminently predictable but a strong body of evidence exists supporting strategies to mitigate adaptive as well as maladaptive forms. Chronic pain is dominated by degenerative joint disease (DJD), which is one of the most significant and under-diagnosed diseases of cats and dogs. DJD is ubiquitous, found in pets of all ages, and inevitably progresses over time; evidence-based strategies for management are established in dogs, and emerging in cats.

**Introduction**

Pain management is central to veterinary practice, not adjunctive. Alleviating pain is not only a professional obligation (recall the veterinarian’s pledge to ‘the relief of animal pain and suffering’) but also a key contributor to successful case outcomes and enhancement of the veterinarian–client–patient relationship. A commitment to pain management identifies a practice as one that is committed to compassionate care; optimum recovery from illness, injury or surgery; and enhanced quality of life.

These Guidelines continue the trend in all branches of medicine toward evidence-based consensus statements that address key issues in clinical practice. Although not a review article, this compilation is a force multiplier for the busy practitioner, consolidating in a single place current recommendations and insights from experts in pain management. These Guidelines are the product of a collaborative effort by the American Animal Hospital Association (AAHA) and the American Association of Feline Practitioners (AAFP). The recommendations of the Guidelines Task Force are evidence based insofar as possible and otherwise represent a consensus of expert opinion.

These Guidelines are designed to expand on the information contained in the 2007 AAHA/AAFP Pain Management Guidelines for Dogs and Cats. The 2015 Guidelines differ from the earlier version in several ways. The first sections are general concepts designed to set the stage for the remaining, more specific content. The 2015 Guidelines also discuss the importance of
an integrated approach to managing pain that does not rely strictly on analgesic drugs. Because pain assessment in animals has become more scientifically grounded in recent years, various clinically validated instruments for scoring pain in both dogs and cats are described. The extensive list of published references includes numerous studies published within the past 3 years, reflecting the rapid pace of advances in managing pain for companion animals. The 2015 Guidelines summarize and offer a discriminating review of much of this new knowledge.

### Types of pain

All types of tissue injury can be generators of pain. Occasionally, pain may occur in the absence of those causative factors. Understanding the mechanisms of pain is the key to its successful prevention and treatment. The pain response is unique to each individual and involves two components:

- The sensory component is **nociception**, which is the neural processing of noxious stimuli;
- The affective component is **pain perception**, which is the unpleasant sensory and emotional experience associated with either actual or potential tissue damage.

Pain is the endpoint of nociceptive input and can only occur in a conscious animal. However, there is also involvement of autonomic pathways and deeper centers of the brain involved with emotion and memory. Hence, pain is a multidimensional experience; it is not just what you feel but also how it makes you feel.⁴

Acute pain has been defined as pain that exists during the expected time of inflammation and healing after injury (up to 3 months), and chronic pain is defined as that which exists beyond the expected duration associated with acute pain. Therapy should be focused on the underlying cause of pain (nociceptive, inflammatory or pathological), rather than on arbitrary labels based on duration.⁴

- **Nociceptive pain** occurs when peripheral neural receptors are activated by noxious stimuli (e.g., surgical incisions, trauma, heat or cold).
- **Inflammatory pain** results gradually from activation of the immune system in response to injury or infection.
- **Pathological pain**, also called maladaptive pain, occurs when pain is amplified and sustained by molecular, cellular and microanatomic changes, collectively termed peripheral and central hypersensitization.

Pathological pain is characterized by hyperalgesia (exaggerated response to noxious stimulus), allodynia (painful response to non-noxious stimuli, such as touch or pressure), expansion of the painful field beyond its original boundaries, and pain protracted beyond the expected time of inflammation and healing. Under some conditions, genomic, phenotypic changes occur that create the condition known as neuropathic pain, whereby pain can be considered a disease of the central nervous system. Those changes are not necessarily chronic. Maladaptive pain, or the risk for it, can occur within a matter of minutes of certain acute pain conditions (e.g., nerve injury, severe tissue trauma, or presence of pre-existing inflammation).
Pain management guidelines

Appropriate pain management requires a continuum of care based on a well thought out plan that includes anticipation, early intervention and evaluation of response on an individual patient basis. It should be noted that response to therapy is a legitimate pain assessment tool. Continuous management is required for chronically painful conditions, and for acute conditions until pain is resolved.

The acronym PLATTER has been devised to describe the continuum of care loop for managing pain. The components of the PLATTER algorithm for pain management are PLan, Anticipate, Treat, Evaluate and Return (Figure 1). The approach provides individualized pain management for any patient and is devised not on a static basis but according to a continuous cycle of plan–treat–evaluate based on the patient’s response.

Figure 1: PLATTER approach to pain management
- **Plan**: Every case should start with a patient-specific pain assessment and treatment plan
- **Anticipate**: The patient’s pain management needs should be anticipated whenever possible so that either preventive analgesia can be provided or, in the case of pre-existing pain, it can be treated as soon as possible
- **Treat**: Appropriate treatment should be provided that is commensurate with the type, severity and duration of pain that is expected
- **Evaluate**: The efficacy and appropriateness of treatment should be evaluated; in many cases, using either a client questionnaire or an in-clinic scoring system
- **Return**: Arguably the most important step, this action takes us back to the patient – where the treatment is either modified or discontinued based on an evaluation of the patient’s response

**Figure 2: Behavioral keys to pain assessment**
When assessing an animal for pain, the following behavioral keys should be considered:
- **Maintenance of normal behaviors**
- **Loss of normal behaviors**
- **Development of new behaviors**

**Recognition and assessment of pain**

The patient’s behavior is key
Because animals are non-verbal and cannot self-report the presence of pain, the burden of pain assumption, recognition and assessment lies with veterinary professionals. It is now accepted that the most accurate method for evaluating pain in animals is not by physiological parameters but by observations of behavior. Pain assessment should be a routine component of every physical examination, and a pain score is considered the ‘fourth vital sign’, after temperature, pulse and respiration.1,2,6

Obtaining a thorough patient history from the owner can help determine abnormal behavior patterns that may be pain related. Pet owners should be educated in observing any problematic behavioral changes in their pet and to contact their veterinarian in such cases.

Pet owners and practitioners should have an awareness of behavior types that are relevant to pain assessment. Those include the animal’s ability to maintain normal behavior, loss of normal behavior, and development of new behaviors that emerge either as an adaption to pain or a response to pain relief (Figure 2). Because behavioral signs of pain are often overlooked or mistaken for other problems, the healthcare team must be vigilant in recognising those anomalies in the total patient assessment.

**It’s not just about drugs**
Classic veterinary medical education places a strong emphasis on treatment of disease through pharmacology and surgery, the esoteric skills that are the domain of the trained clinician. Increasingly, evidence-based data and empirical experience justify a strong role for non-pharmacologic modalities for pain management. A number of those should be considered mainstream options and an integral part of a balanced, individualized treatment plan.

Examples of non-pharmacologic treatments supported by strong evidence include, but are not limited to, cold compression, weight optimization and therapeutic exercise. Treatment options gaining increasing acceptance include acupuncture, physical rehabilitation, myofascial trigger point therapy and therapeutic laser, among other modalities which are discussed later in these Guidelines. In addition, non-pharmacologic adjunctive treatment includes an appreciation of improved nursing care, gentle handling, caregiver involvement, improved home environment, and hospice care. These methods have the critical advantages of increased caregiver–clinician interaction and a strengthening of the human–pet bond. That shared responsibility promotes a team approach and leads to a more complete and rational basis for pain management decisions.5

**Continuum of care**

S P E C I A L  A R T I C L E /  2015 AAHA/AAFP pain management guidelines
Pain scoring tools
Although there is currently no gold standard method for assessing pain in dogs and cats, the Guidelines Task Force strongly recommends utilizing pain scoring tools both for acute and chronic pain. It should be noted that those tools have varying degrees of validation, acute and chronic pain scales are not interchangeable, and canine and feline scales are not interchangeable. The use of pain scoring tools can decrease subjectivity and bias by observers, resulting in more effective pain management, which ultimately leads to better patient care.

Acute pain: characteristics and causes
Acute pain involves both nociceptive and inflammatory components and can be caused by trauma, surgery and medical conditions or diseases. These Guidelines will focus on recognition, prevention and treatment of postsurgical pain.

Multifactorial clinical measurement instruments for acute postsurgical pain
For dogs, a validated, widely used, multifactorial clinical measurement instrument (CMI) for acute pain is the Glasgow Short Form Composite Measure Pain Score. The 4AVet is another composite measure pain score for dogs, reportedly with more interobserver variability than the Glasgow short form, but less biased by sedation.8 Simple, online, practice-friendly numerical rating scales (0 to 4) for acute canine and feline pain have been developed (but not yet validated) by Colorado State University. In cats, a currently validated assessment tool is the UNESP-Botucatu Multidimensional Composite Pain Scale.9,10 That scale and video examples of how it is applied in clinical practice can be accessed online, and a description of Colorado State’s acute pain scales are included in Table 1.

Practical approach to postoperative pain assessment
Validated CMIs are the foundation of rational pain assessment. Those assessment tools provide a simplified approach that encourages regular use by all healthcare members and are based on the following features:
- Observing the patient without interaction (ie, the patient’s orientation in the cage, posture, movement, facial expression, activity level and attitude; Images 1 and 2).
- Observing the patient while interacting with a care-giver (eg, what occurs when the cage door is opened or an animal is coaxed to move).

Table 1
Acute postoperative pain scales

<table>
<thead>
<tr>
<th>Resource</th>
<th>Internet address</th>
<th>Content</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colorado State University Canine Acute Pain Scale</td>
<td><a href="http://www.csuanimalcancercenter.org/assets/files/csu_acute_pain_scale_canine.pdf">www.csuanimalcancercenter.org/assets/files/csu_acute_pain_scale_canine.pdf</a></td>
<td>Psychological and behavioral indicators of pain, Response to palpation</td>
</tr>
<tr>
<td>Colorado State University Feline Acute Pain Scale</td>
<td><a href="http://www.csuanimalcancercenter.org/assets/files/csu_acute_pain_scale_feline.pdf">www.csuanimalcancercenter.org/assets/files/csu_acute_pain_scale_feline.pdf</a></td>
<td>Same as above</td>
</tr>
<tr>
<td>University of Glasgow Short Form Composite Measure Pain Score</td>
<td><a href="http://www.newmetrica.com/cmps">www.newmetrica.com/cmps</a></td>
<td>Clinical decision-making tool for dogs in acute pain, Indicator of analgesic requirement, Includes 30 descriptors and six behavioral indicators of pain</td>
</tr>
</tbody>
</table>

A pain score is considered the ‘fourth vital sign’, after temperature, pulse and respiration.
Observing the patient’s response to palpation of the surgical site (Image 3).

Assigning a numerical score using a dynamic interactive visual analog scale (eg, from 0 for no pain to 10 for the worst possible pain for that procedure).

The re-evaluation interval will depend on the procedure, expected duration of the chosen intervention, and previous pain score. Variability by different observers can be minimized by having the same team member assess the patient throughout the evaluation period. Ideally, the individual patient’s normal temperament should be known for the purposes of comparison with postsurgical appearance and behavior.

### Chronic pain: characteristics and causes

Chronic pain is usually described as either pain that persists beyond the normal healing time or pain that persists in conditions where healing has not or will not occur. In some cases, pain signaling persists in the absence of gross tissue pathology.

The following basic principles are relevant to chronic pain in companion animals:

- Pet owners may not appreciate their pet’s behavior as being an indicator of chronic pain; however, what they might see is increasingly diminished function and mobility that indicate progressive disability. Examples include:
  - Diminished exercise tolerance and general activity.
  - Difficulty standing, walking, taking stairs, jumping or getting up.
  - Decreased grooming (cats especially; Image 4).
  - Changes in urination or defecation habits (Image 5).

- Under-recognized and undermanaged chronic pain can result in premature euthanasia. Conversely, proper recognition and management of chronic pain can be as life-preserving as any other medical treatment in veterinary medicine.

- Degenerative joint disease (DJD) is the inclusive terminology that includes osteoarthritis (OA). Although DJD and OA are often used interchangeably in the literature and in practice, the broader term, DJD, will be used throughout these Guidelines.

### Multifactorial clinical measurement instruments for chronic pain

Observation or reports (eg, in a pre-examination questionnaire) of behavioral changes or abnormalities is the first consideration in recognizing and assessing pain. Thereafter, several standardized, multifactorial CMIs for chronic pain are available to veterinarians, as summarized in Table 2. Such CMIs are chronic pain indices that primarily utilize pet owner observations and input. Ideally, patients with chronic pain should be evaluated with one of the multifactorial CMIs.

<table>
<thead>
<tr>
<th>Helsinki Chronic Pain Index (HCPI)</th>
<th>Canine Brief Pain Inventory (CBPI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cincinnati Orthopedic Disability Index (CODI)</td>
<td>Health-Related Quality of Life (HRQL)</td>
</tr>
<tr>
<td>Liverpool Osteoarthritis in Dogs (LOAD)</td>
<td>Feline Musculoskeletal Pain Index (FMPI)</td>
</tr>
</tbody>
</table>

### Chronic pain: characteristics and causes

Image 3: Following assessment from a distance, palpation of the surgical site is performed to further assess acute pain. Courtesy of Sheilah Robertson

Image 4: Lack of normal behaviors, such as reduced grooming, is commonly seen in painful cats. Image iStock/jvoisey

Image 5: Cats may start to perform abnormal behaviors secondary to pain, such as defecating outside of the litter box, either because the cat cannot get downstairs to the box or it cannot jump into the box. Courtesy of Sheilah Robertson
Pharmacologic intervention of pain

Effective pain management generally involves a balanced or multimodal strategy using several classes of pain-modifying medications. The rationale behind this approach is that it addresses targeting multiple sites in pain pathways, potentially allowing lower doses of each drug and minimizing the potential for side effects associated with any single drug. The choice of medication should be based on anticipated pain levels and individual patient needs. Anticipatory analgesia provided prior to pain onset is more effective than analgesia provided once pain has occurred, contributing to both a dose- and anesthetic-sparing effect.

Opioids

Opioids are the most effective drug class for managing acute pain and can play a role in managing chronic pain. An improved understanding of neuropharmacology and the development of novel formulations of opioids may make it incumbent on veterinarians to remain familiar with their modes of action; the various subtypes within this drug class; and the prevention, recognition and treatment of adverse effects.

While a complete discussion of opioids is beyond the scope of these Guidelines, the Task Force makes the following recommendations for using this class of drugs in dogs and cats:

- Opioids should be used as a routine preoperative medicant, preferentially in combination with a tranquilizer/sedative (eg, acepromazine, midazolam, diazepam or α-2 adrenergic agonist such as dexmedetomidine), when the patient’s condition warrants their use.
- Full μ agonists elicit greater and more predictable analgesia than partial μ agonists or κ agonists. In dogs, the μ antagonist/κ agonist butorphanol, in particular, appears to provide limited somatic analgesia and a very short duration of visceral analgesia.12,13
- In a comparison study, buprenorphine administered before surgery and during wound closure provided adequate analgesia for 6 h following ovariohysterectomy in cats, whereas butorphanol did not.14
- In cats, the subcutaneous (SC) route of opioid administration is not recommended. Intramuscular (IM) and intravenous (IV) routes are preferred both pre- and postoperatively.15 The oral transmucosal or buccal route of administration for buprenorphine may have clinical efficacy as well.16,17
- The individual effect of any opioid, including duration, may vary widely from patient to patient. Postoperative re-evaluation should be made frequently to determine ongoing opioid requirements.
- For a patient undergoing major surgery, whereby ongoing opioid administration can be anticipated, the clinician may choose from the following strategies:
  - Periodic readministration of parenteral opioids.
  - Constant or variable rate infusion. Calculators can be found online.
  - Long-acting formulations and technologies. For dogs there is a Food and Drug Administration (FDA) approved transdermal fentanyl product (Recuvyr; Elanco). Given this canine fentanyl product on the market, the Task Force discourages the use of human commercial fentanyl patches in dogs due to highly variable pharmacokinetics, and risk of either accidental or purposeful human exposure, with potential liability for extralabel use. There is not an expert consensus regarding the utility of fentanyl patches in cats. The FDA has more recently approved a concentrated injectable buprenorphine product for cats (Simbadol; Abbott), which has been formulated to provide a 24 h duration of action when administered as directed.
- Oral opioids. Dogs exhibit a robust first-pass effect of oral opioids. No clinical studies document efficacy, but pharmacokinetics of codeine and hydrocodone suggest possible utility.18 No comparable studies exist for cats.
- Opioids are synergistic with α-2 adrenergic agonists, allowing them to be used in low-dose combinations, either with or without ketamine, to great effect for both sedation and analgesia.
- Opioids play a significant role in human medicine for the treatment of chronic pain and may play an underappreciated role in dogs and cats as well, especially for cancer-related pain and in palliative care patients. That said, clinicians must be vigilant with regard to long-term adverse effects such as constipation, drug tolerance and the potential for diversion by clients.

Non-steroidal anti-inflammatory drugs

The majority of conditions that cause pain have an inflammatory component. Non-steroidal anti-inflammatory drugs (NSAIDs) are a mainstay for management of chronic pain as well as for perioperative use. NSAIDs should be used for their central and peripheral effects in both dogs and cats after consideration of risk factors. There is no indication that any one of the veterinary-approved NSAIDs is associated with any greater or lesser incidence or prevalence of adverse events.19 Canine and feline veterinary-approved

Anticipatory analgesia provided prior to pain onset is more effective than analgesia provided once pain has occurred.
Figure 3: Nine ways to minimize the risks of NSAIDs

- Obtain a complete medication history: Avoid or use extreme caution with concurrent or recent use of NSAIDs and/or corticosteroids (including some nutritional supplements that may contain aspirin or other cyclooxygenase-inhibiting mechanisms). Practitioners should observe the following additional precautions due to potential drug interactions:
  - Avoid with furosemide and use caution with angiotensin-converting enzyme inhibitors.
  - Avoid with potentially nephrotoxic drugs (eg, aminoglycosides, cisplatin).
  - Caution with use of additional multiple highly protein-bound drugs (eg, phenobarbital, digoxin, cyclosporin [cyclosporine], cefovecin, chemotherapy agents).
- Be discriminating in patient selection: Be cautious or avoid NSAIDs in patients with the following existing/anticipated conditions:
  - Low-flow states such as dehydration, hypovolemia, congestive heart failure and hypotension. In such cases, IV fluid support and blood pressure monitoring should be available for anesthetized animals.
  - Renal, cardiac or hepatic dysfunction.
- Provide verbal and written client instructions to avoid the medications described above and to discontinue and alert the hospital at the first sign of an adverse event (see below).
- Recognize the earliest signs of adverse events and withdraw NSAID treatment immediately if those events occur, especially in the case of any GI signs in dogs and cats with diminished appetites.

- Perform laboratory monitoring: The frequency will depend on the risk factor of the patient:
  - Ideally within the first month of initiating therapy then 6 monthly thereafter in low-risk patients.
  - For at-risk patients, monitor every 2–4 months depending on risk factor assessment.
- Utilize a balanced, integrated analgesic approach as part of NSAID-sparing strategies.
- Consider washout periods: Clinically relevant washout periods remain controversial and largely undefined. Based on pharmacokinetics, practitioners who wish to err on the side of caution may want to withhold meloxicam for 5 days and other NSAIDs or short-acting corticosteroids for 7 days prior to initiating treatment with another NSAID. In the case of long-acting corticosteroids, a longer washout period needs to be considered. Aspirin should not be administered because there are safer alternatives. If a course of treatment with aspirin has been started in a dog, the recommended washout period before starting an approved veterinary NSAID is up to 10 days.
- Use gastroprotectants: to either treat suspected gastropathy or prevent its occurrence, especially if no washout period occurs. Proton pump inhibitors, H2 antagonists, misoprostol (the drug of choice in humans) and sucralfate can be helpful.
- Dose optimization: Base dosage on lean body weight. Although there is no definitive evidence that NSAID dose reduction lowers the risk of adverse events, some clinicians recommend titrating to the lowest effective dose.

NSAIDs have demonstrated acceptable safety profiles, which is in contrast to non-approved NSAIDs such as aspirin, ibuprofen, naproxen and meloxicam for human use. Long-term use of low-dose meloxicam is approved in cats in many countries other than the USA.

Adverse events related to NSAID use in dogs and cats can be minimized by appropriate use, as outlined in Figure 3. Although the overall incidence and prevalence of NSAID-related toxicity is unknown, it does appear to be very low relative to the number of doses administered.

Of the adverse events associated with NSAIDs, gastrointestinal (GI) toxicity is the most common. The GI clinical signs associated with NSAID toxicity in dogs include vomiting, diarrhea and inappetence. In cats, inappetence appears to be the most common adverse event. Although unlikely, it is possible for erosions and ulcers to be silent and occur prior to any clinical signs. Studies indicate that NSAIDs that spare cyclooxygenase (COX)-1 produce a lower frequency of GI lesions, although the more highly COX-2 selective inhibitors may actually produce more adverse events when underlying gastric damage is already present.

The leading risk factors for NSAID-associated GI perforations are incorrect dosing, concurrent use with other NSAIDs or corticosteroids, and continued use despite GI signs or anorexia. Signs of GI toxicity usually emerge within 2–4 weeks but can occur at any point during administration. It is critical that veterinarians communicate NSAID toxicity risk factors to pet owners (eg, providing information that describes potential side effects, including the commercial circulars provided by drug manufacturers and instruction on when to stop medication and contact a veterinarian).
Another important side effect associated with NSAIDs is nephrotoxicity. When administered before anesthesia in healthy dogs with controlled modest hypotension, no adverse effect on renal function was detected. However, because some dogs in those studies did develop changes in renal parameters, the importance of maintaining a normotensive state during anesthesia is considered paramount when utilizing preoperative NSAIDs. Preoperative administration in dogs is superior in efficacy to postoperative use, consistent with results of multiple studies performed in humans. Similar studies have not been conducted in cats undergoing anesthesia, but one feline study revealed no alteration in glomerular filtration rate measured by iohexol clearance after 5 days of oral meloxicam. If IV access is not possible and normotension cannot be achieved with certainty, the Task Force recommends limiting the use of NSAIDs to postsurgical administration.

Idiosyncratic hepatocellular necrosis has been reported with various NSAIDs but remains exceedingly rare, at only 1.4 cases/10,000 dogs (0.052%), usually occurring between 2 and 4 weeks after starting treatment. Pre-existing elevated liver enzymes are not a risk factor. Idiosyncratic hepatocellular necrosis is not a true toxicosis but rather an intrinsic, heritable reaction to the molecule being administered. Local anesthetics are considered safe, with adverse events generally limited to very high doses or inadvertent IV administration (bupivacaine especially). The Task Force supports the International Veterinary Academy of Pain Management position that, because of their safety and significant benefit, local anesthetics should be utilized, insofar as possible, with every surgical procedure.

α-2 Adrenergic agonists

α-2 Adrenergic receptors are located with opioid receptors. Thus, used together, opioids and α-2 adrenergic agonists are highly synergistic for sedation and analgesia. α-2 Agonists have a versatile dosing profile. That allows low- and even micro-doses in combination with opioids to be clinically useful and minimizes the cardiovascular effects. Clinicians should be mindful that cardiovascular side effects occur even with very low doses of α-2 adrenergic agonists, that lower doses will have a shorter duration of effect, and that analgesic effects have a shorter duration than the sedative effects.

Ketamine

Ketamine exerts a pain-modifying effect via its N-methyl-D-aspartate receptor antagonist actions. Subanesthetic ketamine constant rate infusion (CRI) in humans prevents pain and has antihyperalgesic and antiallodynic effects. Studies appear to support a similar clinical effect in dogs, although the analgesic effect of ketamine has not yet been studied in a feline surgical model. The International Veterinary Academy of Pain Management has adopted a position that the pain-modifying effects and safety profile of subanesthetic doses of ketamine warrant its use as part of a multimodal approach to transoperative pain management, especially in patients with risk factors that may predispose them to either exaggerated or maladaptive pain states.

Local anesthetics

This is the only class of drug that renders complete analgesia. The totality of evidence in human and animal studies reveals the predictable analgesic and anesthetic drug-sparing effects of local anesthetics. In addition, local anesthetics are reported to be antimicrobial and immunomodulating, and can diminish postoperative maladaptive pain states. They do not appear to delay tissue healing. Local anesthetics can be administered either directly at a simple incision site or at a specific nerve to provide analgesia to a large region (or area). A discussion of the many locoregional blocks that can be utilized in dogs and cats is beyond the scope of these Guidelines, but can be found in several readily accessible resources, and most of those blocks can be readily learned by clinicians.

Local anesthetics are considered safe, with adverse events generally limited to very high doses or inadvertent IV administration (bupivacaine especially). The Task Force supports the International Veterinary Academy of Pain Management position that, because of their safety and significant benefit, local anesthetics should be utilized, insofar as possible, with every surgical procedure.

Therapy should be focused on the underlying cause of pain (nociceptive, inflammatory or pathological) rather than on arbitrary labels based on duration.
Systemic lidocaine
There is strong evidence of the safety and beneficial effects of IV lidocaine on pain after abdominal surgery (although not for other surgeries eliciting somatic pain) in humans and possibly in horses, including both analgesia and return of bowel function. IV lidocaine is anesthetic-sparing in dogs and cats, but current evidence for a pain-modifying effect in these species remains inconclusive. Some investigators discourage the use of IV lidocaine in cats due to negative cardiovascular effects, but successful use in clinical practice has been anecdotally reported.

Various formulations for a combination of morphine, lidocaine and ketamine CRIs have been described in dogs.

Tramadol
In contrast to humans, tramadol in dogs has a very short half-life (1.7 h) and negligible amounts of the opioid M1 metabolite are produced. Pharmacodynamic studies demonstrate the anesthetic-sparing and pain-modifying effect of parenteral tramadol in dogs. Convincing evidence for a pain-modifying effect of oral tramadol, however, remains elusive, and already low plasma levels quickly diminish with sequential administration. One small study of oral tramadol did report a statistically significant increase of mechanical threshold levels in dogs, but only at the 5 and 6 h time points.

In contrast to dogs, cats do produce the µ-agonist M1 metabolite. A pain-modifying effect has been demonstrated in both a thermal threshold and clinical surgical model. There is one case series involving the use of oral tramadol in a flavored compounded form (the drug is otherwise quite bitter). Dose titration, toxicity and safety data are currently lacking in both dogs and cats.

Gabapentin
Gabapentin is an anticonvulsant with analgesic properties that may be primarily derived by down-regulating calcium channels. Because of its efficacy and tolerability, gabapentin is widely used in humans with neuropathic and other maladaptive pain conditions. Along with published clinical case reports in animals, the data suggest a strong rationale for using gabapentin in dogs and cats with similar conditions. One canine study suggested a disease-modifying effect in experimental DJD, but clinical studies are lacking. In cats, one unpublished study demonstrated a benefit of gabapentin in naturally occurring DJD (E Troney 2013), and one case series of chronic musculoskeletal pain has also been published.

There is encouraging evidence to support the use of gabapentin for postsurgical pain in humans, but not yet in dogs and cats. An 8–12 h dosing interval has been suggested based on one publication. The primary adverse effect in dogs appears to be somnolence (also the case in humans), which usually resolves with patient acclimation over several days, allowing for a tapering-up schedule.

Amantadine
Amantadine exerts a pain-modifying effect as an N-methyl-D-aspartate receptor antagonist and remains a drug of interest for chronic pain (but not specifically for DJD) in humans. One study demonstrated utility as an adjunct to NSAIDs in dogs with refractory DJD, and there is one case report utilizing amantadine to treat neuropathic pain in a dog. Toxicity and pharmacokinetic studies have been performed in humans and cats, but not in dogs.

Tricyclic antidepressants
As a class, tricyclic antidepressants (TCAs) are the most effective medications for selective neuropathic pain conditions in humans. In dogs, there exists only a single case report where amitriptyline was used for neuropathic musculoskeletal pain.

Selective serotonin (norepinephrine) reuptake inhibitors
These compounds exert their effect by increasing serotonin with or without norepinephrine in the synaptic cleft. At least one selective serotonin (norepinephrine) reuptake inhibitor (SS[N]RI), duloxetine, has a chronic pain label indication in humans. In dogs, bioavailability is poor and clinical efficacy is lacking.

At this point in the Guidelines, the Task Force wants to emphasize the following:

Many drugs and compounds enhance either monoamines or serotonin expression. Caution should be used when such analgesic agents are used in combination. Examples include tramadol, TCAs (including amitriptyline and clomipramine), SS[N]RIs, amantadine, metoclopramide, selegiline, amitraz, mirtazapine and trazodone.

Acetaminophen
Acetaminophen is contraindicated in cats. In dogs, several early studies revealed a pain-modifying effect in orthopedic surgery, and pharmacokinetic data have been reported.

The literature does not appear to indicate that acetaminophen has a proclivity towards hepatotoxicity in dogs.
Maropitant
Maropitant is a central antiemetic indicated for the treatment of acute canine and feline vomiting, which is often a postsurgical sequela and a contributor to the pain burden. Maropitant works through a blockade of substance-P binding to the neurokinin-1 receptor, which is involved in pain processing. The true pain-modifying effect of maropitant in dogs remains uncertain despite canine studies revealing an anesthetic-sparing effect and a non-inferior effect to morphine in an ovariohysterectomy model.85,86

Bisphosphonates
Administered by IV infusion, this class of drug exerts antosteoclast activity and can contribute to pain relief in dogs with bone cancer.87

Corticosteroids
Corticosteroids are not primarily analgesic drugs, but may exert a pain-modifying effect by reducing inflammation. Their utility as an analgesic therapy in dogs and cats has not been reported.88–91

Polysulfated glycosaminoglycans
A parenterally administered polysulfated glycosaminoglycan (PSGAG) product has regulatory approval for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints. Independent studies support PSGAGs as safe and effective chondroprotectants with possible disease-modifying effects.92–94 The bioavailability and distribution of PSGAGs to inflamed joints in cats has been demonstrated with extra-label SC administration.95

Nutraceuticals and other oral supplements
Oral nutritional supplements represent a wide spectrum of compounds either as single agents or in combinations. Anecdotal evidence for a pain-modifying effect of those products remains mixed. If nutraceuticals and/or herbal supplements are made part of a treatment plan, the Task Force suggests mindfulness towards product quality control; awareness of the potential for drug interactions with other medications (eg, some over-the-counter joint products and herbal mixtures contain aspirin and some may contain herbs such as St John’s wort that interfere with serotonin release or reuptake); and avoidance of ingredients derived from endangered species. In the future, evidence for the pain-modifying effect of cannabinoids and/or their commercial drug derivatives may become evident.

Increasingly, evidence-based data and empirical experience justify a strong role for various non-pharmacologic modalities for pain management.

Non-pharmacologic modalities for pain management

Weight optimization
Adipose tissue secretes a mixture of cytokines that circulate throughout the body, contributing to the pathology of many diseases, including DJD, and to the hypersensitization process in general. Either maintaining or regaining a lean body condition score is central to the treatment of chronic pain.

Acupuncture
The Guidelines Task Force holds that acupuncture offers a compelling and safe method for pain management in veterinary patients and should be strongly considered as a part of multimodal pain management plans.96 It is a minimally invasive treatment that, for most animals, is not uncomfortable, often pleasant, and can be used either alone or in addition to other pain treatment modalities (Image 6). Acupuncture has been recognized by the National Institutes of Health since 1998 as having applications in human medicine, especially pain management. There is a solid and still growing body of evidence for the use of acupuncture for the treatment of pain in veterinary medicine to the extent that it is now an accepted treatment modality for painful animals.97–101

Image 6. Note how comfortable cats usually are for acupuncture therapy. Courtesy of Sheilah Robertson
Physical rehabilitation
Combining modality therapy to decrease pain and restore function is now considered an essential approach for musculoskeletal injury and postsurgical recovery. In the treatment of chronic disease, such as DJD or conformational abnormalities, rehabilitation should be considered an important component of an overall long-term treatment strategy.

The foundation of rehabilitation is therapeutic exercise that aims to restore musculoskeletal strength and function, endurance and proprioception, and reduce pain. Most commonly it involves exercise and manual therapy, including joint mobilizations, massage and myofascial release. Energy-based modalities are also often employed, including neuromuscular electrical stimulation, transcutaneous electrical nerve stimulation, cryotherapy with and without compression, therapeutic ultrasound, therapeutic laser and extracorporeal shockwave therapy.

Myofascial pain syndrome (MPS) is increasingly recognized as an important comorbidity in many chronic pain cases in animals. MPS is acknowledged for the important role it plays in the pathology of DJD, repetitive strain injuries in performance dogs, or as a sequela to orthopedic surgery. The pathophysiology of myofascial pain is a complex syndrome involving motor, sensory and autonomic nerve components that is beyond the scope of these Guidelines, but is well described elsewhere. Treatment of MPS is often essential to regain full function of the affected limb, regardless of the underlying cause.

Nutrition management
In the overweight patient, the prime nutritional emphasis should be achieving a leaner body condition. Weight control diets fortified with omega-3 fatty acids have been shown to be effective at reducing signs associated with canine and feline DJD.

Thermal modification
In acute injury, including surgical areas, cold compression has a demonstrable benefit in reducing pain and inflammation, and promoting return to function. In the case of chronic injury, heat can improve comfort and function through a variety of mechanisms.

Environmental modifications
There is strong evidence that the stress of hospitalization inhibits normal behaviors in animals, including eating, grooming, sleeping and elimination. Fear, anxiety, stress and distress lead to hyperalgesia in both humans and animals. Strategies to mitigate hyperalgesia, therefore, include providing bedding, blankets or clothing from home with familiar scents; allowing visitation of hospitalized pets; separating the dogs from the cats; placing cages so that animals do not see each other; using species-specific synthetic pheromones; and proper handling, especially during procedures.

In patients with DJD, throw rugs and ramps will improve mobility and abilities at home (Image 7).

Chiropractic care
The Guidelines Task Force has not found sufficient, reliable, non-contradictory evidence for the use of chiropractic care for pain management in veterinary medicine at this time. That said, chiropractic care has many well-defined applications in human medicine that have been supported through reliable research.

Homeopathy
Incontrovertible evidence that homeopathy is effective in either human or veterinary medicine for the treatment of pain is lacking. Sole reliance on homeopathy to treat a painful condition is, in essence, withholding pain treatment. Thus, this Task Force discourages the use of homeopathy for the treatment of pain.
Managing surgical pain

The Task Force suggests that pain management for dogs and cats undergoing a surgical procedure includes the following:

- A preoperative opioid plus a tranquilizer/sedative (eg, acepromazine and midazolam or diazepam and dexmedetomidine).
- Administration of an NSAID either pre- or postoperatively based on patient risk factors and clinician preference.
- A local anesthetic.

For patients undergoing procedures with risk factors for more severe, protracted or maladaptive postoperative pain states, the following interventions or drugs should be strongly considered:

- Cold compression.
- α-2 Adrenergic agonist.
- Ketamine CRI.
- Lidocaine CRI.
- Gabapentin.
- Epidural anesthetic(s).
Managing pain associated with DJD

Overview of DJD in companion animals

DJD, including OA, is one of the most significant and underdiagnosed diseases of cats and dogs. DJD is clinically relevant because of its overall prevalence and universal incidence in older animals. Whereas diagnostic approaches for canine DJD are well established, the best tools for diagnosis of feline DJD are still being developed.

The pain treatment continuum for DJD begins with the onset of disease, which usually starts at a very young age in dogs (eg, conformational etiology) and cats (unknown etiology), and persists throughout the animal’s life. Perhaps more so than any other pain condition, the management of DJD benefits from an integration of both pharmacologic and non-pharmacologic treatments. Once a diagnosis is made, treatment goals, expectations and outcome measures should be considered prior to initiating any treatment. The care-giver is an essential part of any treatment program and should be considered a part of the team.

Canine DJD: therapeutic considerations

Because early intervention can delay the onset and severity of DJD, the Task Force emphasizes that chief among all preventive and treatment modalities for canine DJD is weight optimization. Maintaining a lean body condition from an early age demonstrably minimizes DJD development in predisposed breeds.129–131 In overweight patients, weight loss alone, even a modest 6.1–8.85%, improves clinical signs of DJD.132 There is strong evidence to support the use of NSAIDs for the management of DJD pain in dogs. Data on the safety and efficacy of long-term NSAID administration in dogs appear to suggest an overall benefit from this modality for a sustained period of time at labeled doses and intervals, provided the patient does not have additional risk factors.22 NSAID therapy should be tailored to suit every individual patient’s needs. Veterinary NSAIDs studied for chronic use (between 28 days and 1 year) demonstrated satisfactory safety profiles in dogs, with 95–97% of dogs able to receive their NSAID at labeled doses and intervals without adverse effects for the duration of the study.22 There is currently no evidence that a higher risk for NSAID-induced adverse effects exists as the duration of treatment increases. Some dogs may require several weeks of NSAID treatment before clinical improvement is noted.133

In addition to NSAIDs, there are other options to consider. First, PSGAGs are more likely to have a beneficial effect when given early in the disease process.52 As mentioned earlier, an FDA-approved product with established efficacy and safety is available. Secondly, data supporting analgesia and functional improvement from therapeutic exercise are well established in humans and are beginning to accrue in dogs.134 Thirdly, a systematic review analyzing data from several placebo-controlled blinded studies affirmed the utility of diets rich in eicosapentaenoic acid for dogs with DJD.135 Various other strategies can be (and often are) employed, but their supporting evidence is weak, conflicting or altogether lacking at present.

Feline DJD: therapeutic considerations

Until the early 2000s, little attention was paid to DJD in cats; however, estimates from published studies suggest that 40–92% of all cats may have some clinical signs associated with DJD.136 Feline DJD is now recognized as a serious welfare problem, particularly in older cats, which is a rapidly growing demographic.136,137 The most frequently affected joints appear to be the hip, stifle, tarsus, elbow, thoracolumbar and lumbosacral area.137 For each 1 year increase in a cat’s age, the expected total DJD score increases by an estimated 13.6%. Moreover, there is a dramatic increase in the prevalence and burden of DJD at about 10 years of age. A diagnosis of feline DJD is based on a thorough history reflecting changes in behavior and lifestyle, physical exam findings (Image 8), and possible radiographic evidence.

Perhaps more so than any other pain condition, the management of DJD benefits from an integration of both pharmacologic and non-pharmacologic treatments.
Behavioral changes are the most common signs of DJD-associated pain in cats. Feline DJD is usually bilateral – so, although cats rarely limp, they are likely to be stiff, have a less fluid gait, become less active (especially at night) and exhibit decreased jumping frequency or jumping height. Owners often note that their cats are very stiff going up or down stairs. The cat may resist handling, petting, or stroking of the back or limbs. Showing the owner a list of the common pain-related behaviors caused by DJD is helpful in making the diagnosis (Table 3).

It should be assumed that a senior cat has some DJD, and every effort should be made to incorporate gentle handling techniques. Low-dose meloxicam (ie, 0.01–0.03 mg/kg orally q24h) is effective in treating arthritic cats and is well tolerated, even in cats with CKD provided their clinical status is stable. Meloxicam is effective when administered once q24h and is palatable for most patients, making it easy to administer. In Europe, Australasia and many countries, meloxicam is approved for long-term use in cats at a dose of 0.05 mg/kg q24h. The oral route of administration and long-term use of meloxicam in cats remain off-label in the USA.

Robenacoxib is a COX-2 selective NSAID approved for surgical pain in cats. It has not been studied for either feline DJD or in older cats but there are long-term safety data in young cats (ie, 5 x the recommended dosage for 6 months and 10 x the recommended dosage for 6 weeks). Dosing on lean body weight, close monitoring of clinical status (especially appetite), regular laboratory monitoring, and appropriately modifying the treatment plan are recommended for cats receiving NSAIDs. NSAIDs should be used with caution on a case-by-case basis in cats with DJD, and cat owners should be advised that, in the USA, use of NSAIDs for feline DJD is an extra-label treatment.

<table>
<thead>
<tr>
<th>Behavioral component</th>
<th>Indicators of DJD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interaction with others</td>
<td>Withdrawal, hiding, increased ‘clinginess’, irritability when touched, aggression toward other cats or humans</td>
</tr>
<tr>
<td>Appetite</td>
<td>Declines but cat continues to eat</td>
</tr>
<tr>
<td>Posture</td>
<td>Hunched, head lowered, sitting or lying abnormally, squinting, facial expression indicating discomfort</td>
</tr>
<tr>
<td>Grooming</td>
<td>Declines, matting of fur, over-grooming of painful area</td>
</tr>
<tr>
<td>Litter box use</td>
<td>Decline in bowel movements, house soiling, inability to get into box</td>
</tr>
<tr>
<td>Play</td>
<td>Reduced overall, reduced jumping</td>
</tr>
<tr>
<td>Vocalization</td>
<td>Increased but decreased greeting and other pleasant vocalizations, hissing if touched on painful area, squinting if acute pain</td>
</tr>
<tr>
<td>Mobility</td>
<td>Not jumping as often or as high, hesitant to jump, difficulty going up or down stairs, stiffness, less active, difficulty getting into or out of litter box, sleeping in more easily accessible locations</td>
</tr>
</tbody>
</table>

Behavioral changes are the most common signs of DJD-associated pain in cats. Feline DJD is usually bilateral – so, although cats rarely limp, they are likely to be stiff, have a less fluid gait, become less active (especially at night) and exhibit decreased jumping frequency or jumping height. Owners often note that their cats are very stiff going up or down stairs. The cat may resist handling, petting, or stroking of the back or limbs. Showing the owner a list of the common pain-related behaviors caused by DJD is helpful in making the diagnosis (Table 3).

It should be assumed that a senior cat has some DJD, and every effort should be made to incorporate gentle handling techniques. Low-dose meloxicam (ie, 0.01–0.03 mg/kg orally q24h) is effective in treating arthritic cats and is well tolerated, even in cats with CKD provided their clinical status is stable. Meloxicam is effective when administered once q24h and is palatable for most patients, making it easy to administer. In Europe, Australasia and many countries, meloxicam is approved for long-term use in cats at a dose of 0.05 mg/kg q24h. The oral route of administration and long-term use of meloxicam in cats remain off-label in the USA.

Robenacoxib is a COX-2 selective NSAID approved for surgical pain in cats. It has not been studied for either feline DJD or in older cats but there are long-term safety data in young cats (ie, 5 x the recommended dosage for 6 months and 10 x the recommended dosage for 6 weeks). Dosing on lean body weight, close monitoring of clinical status (especially appetite), regular laboratory monitoring, and appropriately modifying the treatment plan are recommended for cats receiving NSAIDs. NSAIDs should be used with caution on a case-by-case basis in cats with DJD, and cat owners should be advised that, in the USA, use of NSAIDs for feline DJD is an extra-label treatment.

<table>
<thead>
<tr>
<th>Behavioral component</th>
<th>Indicators of DJD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Interaction with others</td>
<td>Withdrawal, hiding, increased ‘clinginess’, irritability when touched, aggression toward other cats or humans</td>
</tr>
<tr>
<td>Appetite</td>
<td>Declines but cat continues to eat</td>
</tr>
<tr>
<td>Posture</td>
<td>Hunched, head lowered, sitting or lying abnormally, squinting, facial expression indicating discomfort</td>
</tr>
<tr>
<td>Grooming</td>
<td>Declines, matting of fur, over-grooming of painful area</td>
</tr>
<tr>
<td>Litter box use</td>
<td>Decline in bowel movements, house soiling, inability to get into box</td>
</tr>
<tr>
<td>Play</td>
<td>Reduced overall, reduced jumping</td>
</tr>
<tr>
<td>Vocalization</td>
<td>Increased but decreased greeting and other pleasant vocalizations, hissing if touched on painful area, squinting if acute pain</td>
</tr>
<tr>
<td>Mobility</td>
<td>Not jumping as often or as high, hesitant to jump, difficulty going up or down stairs, stiffness, less active, difficulty getting into or out of litter box, sleeping in more easily accessible locations</td>
</tr>
</tbody>
</table>
Treatment of DJD in cats should focus on environmental modification (Images 11 and 12) in addition to pharmacologic therapy. In addition to steps and ramps to facilitate access to favorite elevated areas, additional litter boxes with at least one low side will make access easier. Owners can also provide physical therapy by implementing play times using favorite toys to increase exercise and mobility.

**When pain persists: hospice and palliative care**

Hospice is designed to provide compassionate comfort and care to patients at the end of their lives and to support their families in the bereavement process. Hospice care for terminally ill patients is recommended when life expectancy is less than 6 months. Palliative care is the active, total care of patients with disease that is not responsive to curative treatment, with pain control being the paramount feature. The goal is achievement of the best quality of life (QoL) for patients and their families. This assumes ongoing assessment of QoL in the terminally ill patient. User-friendly QoL assessment scales are available to help veterinarians, veterinary staff and owners make proper assessments and decisions at the end of a patient’s life. It is generally agreed that the pet’s care-giver is best suited to evaluate QoL, but a team approach (discussed on page 266) emphasizing regular communication is important to provide empathetic support when end-of-life decisions are made.

An integrated approach that includes non-pharmacologic modalities is typically best for palliative care and hospice patients with cancer because their disease is often associated with features of both acute and chronic pain. In cases of palliative radiation, either a smaller number or lower doses of radiation can make treatment protocols more tolerable for the patient and agreeable to the owner.

Environmental modification, physical therapy (eg, massage, acupuncture and therapeutic laser) or ultrasound can be useful additions to the pain management plan. Providing nutritional support via feeding tube can be helpful where eating is otherwise difficult or painful. In cases involving hospice and palliative care, it is important to encourage clients to have realistic expectations of the outcomes involving their pets. As well as explanations of probable outcomes, this involves providing the client with end-of-life choices involving the pet. Euthanasia is an option that relieves pain and suffering and should be discussed as a reasonable and humane alternative at an appropriate point. Euthanasia may be a topic that the veterinary team initiates if the pet owner does not.

**Euthanasia is an option that relieves pain and suffering and should be discussed as a reasonable and humane alternative at an appropriate point.**
A team approach and client education: creating an environment for success

Primary care practices should be committed to educating the healthcare team and its clients about prevention, recognition, assessment and treatment of pain. A team approach and consistent pain management messages directed at clients will help ensure patient comfort at all stages of treatment. The client is often considered the most important member of the healthcare team.

Each healthcare team member should be able to recognize pain-associated behavior in animals, as described earlier in these Guidelines, and know how to respond appropriately. Table 4 provides examples of how healthcare team members should respond to patients experiencing pain.

Staff training and education

Ideally, every healthcare team member should have a defined role in managing animal pain. Staff and client education should address conditions associated with pain; its prevention and treatment; and appropriate interaction, handling and nursing care involving the patient. Medical rounds and staff meetings are effective tools in making sure that all staff members are aware of the individualized pain management needs of every hospitalized patient. Having a patient advocate for each hospitalized animal will enable a highly accurate and individualized evaluation of the patient and ensure successful treatment. Recall that Table 1 lists pain indices relying on observation and input by clinical personnel. Those assessment tools complement the pain-scoring instruments based on owner observation and input, which are listed in Table 2.

Client education and instructions

With each pain management plan, it is important that the client be given specific instructions, both verbally and in writing. Potential adverse drug effects and action to be taken should be emphasized. It is advisable to provide a hands-on demonstration of how to administer medications and handle the pet at home. To reinforce verbal information about pain assessment, provide handouts that discuss general information about animal pain and any side effects of medications. Compliance will improve if the pet owner understands the treatment schedule and a demonstration of how to administer oral medications is given. Clients should be encouraged to address their concerns about the pet’s condition and treatment plan via e-mail, phone or follow-up consultations.

Table 4 Healthcare team member responsibilities for pain management

<table>
<thead>
<tr>
<th>Role</th>
<th>Responsibilities</th>
</tr>
</thead>
<tbody>
<tr>
<td>Veterinary</td>
<td>Assess pain in every patient regardless of appointment type (eg, wellness, sick, follow-up)</td>
</tr>
<tr>
<td></td>
<td>Develop standard operating procedures for the practice to prevent pain, including the following:</td>
</tr>
<tr>
<td></td>
<td>- Weight optimization and prevention of dental disease</td>
</tr>
<tr>
<td></td>
<td>- Handling and hospitalization to prevent fear and pain</td>
</tr>
<tr>
<td></td>
<td>- PLATTER (see Figure 1) to follow up and modify plan</td>
</tr>
<tr>
<td></td>
<td>Provide staff education on:</td>
</tr>
<tr>
<td></td>
<td>- Effective client communication and education</td>
</tr>
<tr>
<td></td>
<td>- Preventive pain strategies</td>
</tr>
<tr>
<td></td>
<td>- Recognition and assessment of pain</td>
</tr>
<tr>
<td></td>
<td>- Drug interactions and adverse effects</td>
</tr>
<tr>
<td>Technician</td>
<td>Obtain medication history</td>
</tr>
<tr>
<td></td>
<td>Anticipate painful procedures</td>
</tr>
<tr>
<td></td>
<td>Recognize signs of pain and alert veterinarian</td>
</tr>
<tr>
<td></td>
<td>Treat as directed by a veterinarian and update records</td>
</tr>
<tr>
<td></td>
<td>Assess postoperative patients and record pain score</td>
</tr>
<tr>
<td></td>
<td>Assess chronic pain patients and record pain score</td>
</tr>
<tr>
<td></td>
<td>Maintain effective client communication and education</td>
</tr>
<tr>
<td>Patient-care personnel</td>
<td>Prior to examination:</td>
</tr>
<tr>
<td></td>
<td>- Note possible causes of pain</td>
</tr>
<tr>
<td></td>
<td>- Note any patient behavioral changes</td>
</tr>
<tr>
<td></td>
<td>During the examination:</td>
</tr>
<tr>
<td></td>
<td>- Proper handling</td>
</tr>
<tr>
<td></td>
<td>- Other stress/anxiety-relieving techniques</td>
</tr>
<tr>
<td></td>
<td>Following the examination:</td>
</tr>
<tr>
<td></td>
<td>- Monitor patient’s behavior</td>
</tr>
<tr>
<td></td>
<td>- Contact client about questions or concerns</td>
</tr>
<tr>
<td></td>
<td>- Set follow-up appointment</td>
</tr>
<tr>
<td></td>
<td>Housing should be stress/anxiety-relieving</td>
</tr>
</tbody>
</table>

Ideally, every healthcare team member should have a defined role in managing animal pain.

Acknowledgements

These Guidelines were prepared by a Task Force of experts convened by the American Animal Hospital Association and the American Association of Feline Practitioners. The AAHA secured sponsorship of an educational grant in accordance with their policies from Abbott Animal Health, Elanco Companion Animal Health, Merial, Novartis Animal Health and Zoetis. This report was subjected to review in accordance with both AAFP and AAHA policies.

Funding

These Guidelines were supported by an educational grant to AAHA from Abbott Animal Health, Elanco Companion Animal Health, Merial, Novartis Animal Health and Zoetis.

Conflict of interest

Mark Epstein has previously consulted for Abbott, Elanco and Merial. Sheilah Robertson is a key opinion leader for Novartis Animal Health.
## Table 5  Summary of appropriate interventions for pain in dogs and cats

<table>
<thead>
<tr>
<th>DJD dog</th>
<th>DJD cat (with CKD)</th>
<th>Soft tissue abdominal surgery</th>
<th>Dental surgery</th>
<th>Orthopedic procedure</th>
<th>Hospital procedures:</th>
<th>Comments/details</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>X (2)</td>
<td>X (3)</td>
<td>X X</td>
<td>X X X X X X X X</td>
<td>IV catheterization</td>
<td>X (5) X (8)</td>
</tr>
<tr>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (6)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Consider local</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>anesthetic cream</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Urinary catheterization</td>
<td>X (9) X (10)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (6) X X</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Bone marrow aspiration</td>
<td>X (9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (6) X X</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Radiography (painful</td>
<td>X (9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>and/or arthritic patient)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Anal sac expression</td>
<td>X (9)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Ear cleaning</td>
<td>X (7) X (7) X (7)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thoracocentesis and/or abdominocentesis</td>
<td>X (9) X</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X (6) X</td>
</tr>
</tbody>
</table>

### Notes:
1. Local or regional analgesia may be useful in localization of pain and short term relief of significant DJD pain
2. See discussion on pages 256–258 concerning the use of non-steroidal anti-inflammatory drugs (NSAIDs) in cats
3. The addition of other analgesic drugs will depend on patient characteristics and extent of the procedure
4. These interventions will be helpful pre- and postoperatively for the relief and/or prevention of postoperative and chronic pain
5. Ideally premedications should precede other preparations for general anesthesia such as placement of an IV catheter
6. These are invasive procedures and should be treated as such to optimize patient care and minimize trauma/tissue damage and post-procedural pain
7. The level of intervention will be tailored to the invasiveness of the procedure. Deep ear cleaning will require more significant intervention than superficial cleaning in most cases
8. In non-emergency settings (eg, routine pre-surgical application)
9. Chemical restraint in lieu of manual restraint when patient is fractious, distressed or otherwise intolerant of the procedure
10. Sterile lidocaine lubricant; caution in cases of urethral or bladder mucosal damage

GAGs = glycosaminoglycans, CKD = chronic kidney disease, DJD = degenerative joint disease

### Abbreviations used in the Guidelines

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AAHA</td>
<td>American Animal Hospital Association</td>
</tr>
<tr>
<td>AAFP</td>
<td>American Association of Feline Practitioners</td>
</tr>
<tr>
<td>CKD</td>
<td>Chronic kidney disease</td>
</tr>
<tr>
<td>CMI</td>
<td>Clinical measurement instrument</td>
</tr>
<tr>
<td>CRI</td>
<td>Constant rate infusion</td>
</tr>
<tr>
<td>COX</td>
<td>Cyclooxygenase</td>
</tr>
<tr>
<td>DJD</td>
<td>Degenerative joint disease</td>
</tr>
<tr>
<td>GAGs</td>
<td>Glycosaminoglycans</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>MPS</td>
<td>Myofascial pain syndrome</td>
</tr>
<tr>
<td>NSAID</td>
<td>Non-steroidal anti-inflammatory drug</td>
</tr>
<tr>
<td>OA</td>
<td>Osteoarthritis</td>
</tr>
<tr>
<td>PSGAG</td>
<td>Polysulfated glycosaminoglycan</td>
</tr>
<tr>
<td>SS(N)RI</td>
<td>Selective serotonin (norepinephrine) reuptake inhibitor</td>
</tr>
<tr>
<td>SC</td>
<td>Subcutaneous</td>
</tr>
<tr>
<td>TCA</td>
<td>Tricyclic antidepressant</td>
</tr>
<tr>
<td>QoL</td>
<td>Quality of life</td>
</tr>
</tbody>
</table>
SUMMARY POINTS

- Effective pain management is an essential component of companion animal medicine. It reduces disease morbidity, facilitates recovery, enhances quality of life, and solidifies the relationship between the veterinarian, client and pet.
- Behavioral changes are the principal indicator of pain and its resolution, for which there are now several validated clinical scoring instruments.
- Pain is not an isolated event but instead exists either as a continuum of causation, progression and resolution or as a chronic condition. Thus, treatment of pain should consist of a continuum of care in the form of anticipatory analgesia through the anticipated pain period followed by longer term or even chronic treatment that relies on periodic reassessment of the patient's response.
- Effective pain management is integrative in two respects. First, it does not rely solely on pharmacologic methods but also uses a variety of non-pharmacologic modalities; not least of those is gentle handling and nursing care of the patient in the context of a stress-free physical environment. When considering either non-pharmacologic methods or hospice care that may be outside the immediate skills or services provided by the primary practice, the veterinarian should have a list of experts for referral in place. A second aspect of integrative pain management is the multimodal use of medications that either block or modify multiple pain pathways. A multimodal approach also reduces reliance on any single agent, minimizing the potential for adverse drug events.
- Pain management in clinical practice is a team effort, with the pet owner functioning as an integral part of the team. All healthcare team members should have a defined role in the practice’s approach to providing compassionate care to its patients. That enables the practice to speak with one voice and in a consistent manner in the implementation of pain management protocols.
- Client education is a key component that enables the pet owner to manage pain in the home setting. Direct involvement of the client in pain management efforts is consistent with the continuum of care concept and a demonstration of the practice’s commitment to the pet’s quality of life.
- A fully integrated approach to pain management, involving recognition and systematic assessment, pharmacologic and non-pharmacologic methods, and including both healthcare team members and the pet owner, ensures that everything possible has been done to relieve a patient’s pain once it enters the practice’s care.

References

4 Woolf CJ. What is this thing called pain? J Clin Invest 2010; 120: 3742–3744.
14 Warne LN, Beths T, Holm M, et al. Evaluation of the perioper-
51 Kongara K, Chambers JP and Johnson CB. Effects of tramadol, morphine or their combination in dogs undergoing ovariohysterectomy on peri-operative electroencephalographic responses.


89 Pelletier JP and Martel-Pelletier J. In vivo protective effects of prophylactic treatment with tiaprofenic acid or intraarticular corticosteroids on osteoarthritic lesions in the experimental dog model. [J Rheumatol Suppl 1991; 27: 127–130.]  
100 Petermann U. Comparison of pre- and post-treatment pain scores of twenty one horses with lamiitis treated with acupuncture and topical low level impulse laser therapy. AJTCVM 2011; 6: 13–25.  
122 Kim YM, Lee JK, Abd el-aty AM, et al. Efficacy of dog-appeasing pheromone (DAP) for ameliorating separation-related behav-
SPECIAL ARTICLE / 2015 AAHA-AAFP pain management guidelines